Roche Holding AG
🇨🇭Switzerland
- Country
- 🇨🇭Switzerland
- Ownership
- Public
- Established
- 1896-01-15
- Employees
- 103.6K
- Market Cap
- $270.5B
- Website
- http://www.roche.com
A Study of Administration of Peginterferon Alfa-2a [Pegasys] by Autoinjector Versus Pre-filled Syringe in Patients With Chronic Hepatitis C
Phase 1
Completed
- Conditions
- Hepatitis C, Chronic
- Interventions
- Device: AutoinjectorDevice: Pre-filled syringe
- First Posted Date
- 2010-03-16
- Last Posted Date
- 2016-02-09
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 60
- Registration Number
- NCT01087944
A Study of Peginterferon Alfa-2a [PEGASYS] in Patients With Chronic Hepatitis B Who Are HBeAg Positive
Phase 4
Completed
- Conditions
- Hepatitis B, Chronic
- Interventions
- Drug: peginterferon alfa-2a [PEGASYS]Drug: Adefovir
- First Posted Date
- 2010-03-12
- Last Posted Date
- 2016-11-02
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 265
- Registration Number
- NCT01086085
A Study of Xeloda (Capecitabine) in Breast Cancer Patients With Central Nervous System (CNS) Progression
- First Posted Date
- 2010-03-01
- Last Posted Date
- 2016-11-02
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 3
- Registration Number
- NCT01077726
A Study of Avastin (Bevacizumab) With XELOX or FOLFOX in Patients With Metastatic Colorectal Cancer and Disease Progression Under First-line FOLFIRI and Avastin
Phase 2
Completed
- Conditions
- Colorectal Cancer
- Interventions
- First Posted Date
- 2010-03-01
- Last Posted Date
- 2014-12-15
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 75
- Registration Number
- NCT01077739
A Study of Avastin (Bevacizumab) in Combination With Gemcitabine With or Without Cisplatin in First-Line Treatment of Elderly Patients With Non-Small Cell Lung Cancer
Phase 2
Completed
- Conditions
- Non-Squamous Non-Small Cell Lung Cancer
- Interventions
- First Posted Date
- 2010-03-01
- Last Posted Date
- 2015-10-08
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 86
- Registration Number
- NCT01077713
An Observational Study on Patients With Rheumatoid Arthritis Treated With MabThera (Rituximab)
- First Posted Date
- 2010-02-25
- Last Posted Date
- 2016-11-02
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 151
- Registration Number
- NCT01075477
An Observational Study on Infusion-related Adverse Events at Administration of MabThera (Rituximab) in Patients With Chronic Lymphocytic Leukemia
- First Posted Date
- 2010-02-22
- Last Posted Date
- 2016-11-01
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 92
- Registration Number
- NCT01072240
An Observational Study on the Safety and Effectiveness of Rituximab in Patients With Severe Active Rheumatoid Arthritis
- First Posted Date
- 2010-02-19
- Last Posted Date
- 2016-02-22
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 1653
- Registration Number
- NCT01071798
An Exploratory Study of RO4929097 in Patients With Recurrent or Refractory Non-Small Cell Lung Cancer
Phase 2
Completed
- Conditions
- Non-Squamous Non-Small Cell Lung Cancer
- Interventions
- Drug: RO4929097
- First Posted Date
- 2010-02-18
- Last Posted Date
- 2016-11-02
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 7
- Registration Number
- NCT01070927
PROPHESYS 1: An Observational Study on Predictors of Response in Treatment-naïve Patients With Chronic Hepatitis C Virus (HCV)Treated With Pegasys (Peginterferon Alfa-2a)
Completed
- Conditions
- Hepatitis C, Chronic
- Interventions
- Drug: Peginterferon alfa-2a (Pegasys®)
- First Posted Date
- 2010-02-18
- Last Posted Date
- 2016-06-15
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 4680
- Registration Number
- NCT01070550
© Copyright 2025. All Rights Reserved by MedPath